

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	25.5	98.2	(63.5-144.9)	Male	23	16.8	137.0	(86.8-205.5)
Female	7	9.1	77.0	(30.8-158.7)	Female	18	12.9	139.3	(82.5-220.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.2	116.3	(42.5-253.1)	Male	7	4.1	172.5	(69.1-355.4)
Female	4	4.1	nc	(nc-nc)	Female	5	2.9	172.7	(55.6-403.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	14.0	107.2	(59.9-176.8)
Female	94	94.6	99.4	(80.3-121.7)	Female	12	11.8	102.0	(52.6-178.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.9	127.8	(41.2-298.3)	Male	5	10.4	47.9	(15.4-111.7)
<u>Colon / Rectum</u>					Female	7	4.6	151.0	(60.5-311.2)
Male	24	34.4	69.7	(44.7-103.7)	<u>Ovary</u>				
Female	37	30.2	122.4	(86.2-168.7)	Female	4	9.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.1	85.0	(31.0-185.0)	Male	8	8.0	100.0	(43.1-197.1)
Female	3	1.7	nc	(nc-nc)	Female	6	7.6	78.7	(28.7-171.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	106	106.1	99.9	(81.8-120.8)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.9	101.7	(37.1-221.3)
Male	11	13.2	83.2	(41.5-149.0)	Female	3	3.3	nc	(nc-nc)
Female	6	7.6	78.4	(28.6-170.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.6	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	16	14.9	107.6	(61.5-174.7)
Male	14	8.8	159.8	(87.3-268.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.3	110.4	(44.2-227.5)	Female	27	22.0	122.6	(80.8-178.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.6	106.1	(42.5-218.6)	Male	352	355.7	99.0	(88.9-109.9)
Female	1	2.1	nc	(nc-nc)	Female	350	322.3	108.6	(97.5-120.6)
<u>Lung and Bronchus</u>									
Male	54	48.6	111.1	(83.5-145.0)					
Female	45	46.2	97.4	(71.0-130.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;